The alliance provides clinical trial sponsors direct access to the world’s most experienced team of thorough QT scientists, unparalleled subject enrollment and bed capacity, integrated study management and accelerated data delivery, said Cetero Research.
The partnership’s turnkey offering also streamlines sponsors’ vendor selection, quality evaluation and contracting processes, added Cetero Research.
Jerry Merritt, CEO of Cetero Research, said: “When selecting a clinic and core lab for cardiac safety trials, customers consistently tell us their most important needs are hands-on experts, top-quality facilities and seamless project controls.
“By creating the first true integration between a top clinical pharmacology CRO and a top core lab, the Cetero-Cardiocore alliance is able to provide clients with a turnkey solution to their cardiac safety needs, with one contract, one project manager, and one final report.”